Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study.

[1]  J. V. van Hooff,et al.  A pilot study on sublingual administration of tacrolimus , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  O. Kusnik-Joinville,et al.  Prevalence and treatment of diabetes in France: trends between 2000 and 2005. , 2008, Diabetes & metabolism.

[3]  A. Borobia,et al.  Sublingual administration of tacrolimus in a renal transplant patient , 2008, Journal of clinical pharmacy and therapeutics.

[4]  R. Lange,et al.  Alternatives to Heart Transplantation , 2007 .

[5]  B. Díaz Molina,et al.  Study of the renal function in nonrenal organ transplantation. , 2006, Transplantation proceedings.

[6]  E. Sklar.  Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? , 2006, AJNR. American journal of neuroradiology.

[7]  J. Trotter,et al.  Immunosuppression: Evolution in Practice and Trends, 1994–2004 , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.

[9]  Koichi Inoue,et al.  Evaluation and analysis of exposure levels of di(2-ethylhexyl) phthalate from blood bags. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[10]  H. Kramer,et al.  Comparison of sublingual to oral tacrolimus administration in lung transplantation , 2005 .

[11]  H. Reichenspurner,et al.  Overview of tacrolimus-based immunosuppression after heart or lung transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  Philip F Halloran,et al.  Immunosuppressive drugs for kidney transplantation. , 2004, The New England journal of medicine.

[13]  C. Staatz,et al.  Sampling Times for Monitoring Tacrolimus in Stable Adult Liver Transplant Recipients , 2004, Therapeutic drug monitoring.

[14]  M. Higa,et al.  Nitroglycerin spray rapidly improves pain in a patient with chronic painful diabetic neuropathy , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[15]  S. Nakajima,et al.  Investigation of the release behavior of diethylhexyl phthalate from polyvinyl chloride tubing for intravenous administration based on HCO60. , 2003, International journal of pharmaceutics.

[16]  M. Veroux,et al.  Severe Neurotoxicity in Tacrolimus-Treated Living Kidney Transplantation in Two Cases , 2003, Urologia Internationalis.

[17]  N. Undre,et al.  Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. , 2002, Transplantation proceedings.

[18]  S. Palmer,et al.  Sublingual Tacrolimus for Immunosuppression in Lung Transplantation , 2002, American journal of respiratory medicine : drugs, devices, and other interventions.

[19]  I. Bekersky,et al.  Effect of Time of Meal Consumption on Bioavailability of a Single Oral 5 mg Tacrolimus Dose , 2001, Journal of clinical pharmacology.

[20]  I. Bekersky,et al.  Effect of Low‐ and High‐Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects , 2001, Journal of clinical pharmacology.

[21]  J. Littlewood,et al.  Control of Malabsorption in Cystic Fibrosis , 2000, Paediatric drugs.

[22]  J. Briegel,et al.  Optimization of the immunosuppressive protocol after lung transplantation. , 1999, Transplantation.

[23]  J. Briegel,et al.  Tacrolismus (FK506) as Primary Immunosuppressant After Lung Transplantation , 1999 .

[24]  N. Undre,et al.  The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[25]  al-Waili Ns,et al.  Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine. , 1999 .

[26]  J. Briegel,et al.  Tacrolimus-based immunosuppressive protocols in lung transplantation. , 1999, Transplantation proceedings.

[27]  G. Trimarchi,et al.  Oral toxicity of bis(2-ethylhexyl) phthalate during pregnancy and suckling in the Long-Evans rat. , 1998, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  J. Treluyer,et al.  Drug Disposition in Cystic Fibrosis , 1998, Clinical pharmacokinetics.

[29]  N. Undre,et al.  Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients , 1998, European Journal of Drug Metabolism and Pharmacokinetics.

[30]  Z. Kiss,et al.  Clinical Application of the Nitroglycerin Lingual Spray , 1998, American journal of therapeutics.

[31]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[32]  B. Griffith,et al.  Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. , 1996, Transplantation proceedings.

[33]  C. McGregor,et al.  Clinical Investigations: Lung TransplantationGastroparesis After Lung Transplantation: Potential Role in Postoperative Respiratory Complications , 1995 .

[34]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[35]  G. Crabtree,et al.  Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. , 1994, The Journal of biological chemistry.

[36]  C. Klee,et al.  Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Schreiber,et al.  Immunophilin-ligand complexes as probes of intracellular signaling pathways. , 1991, Transplantation proceedings.

[38]  T. Starzl,et al.  Pharmacokinetics of FK 506 in transplant patients. , 1991, Transplantation proceedings.

[39]  S. Todo,et al.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. , 1991, Transplantation proceedings.

[40]  L A Herzenberg,et al.  Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Okuhara,et al.  Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. , 1987, Transplantation proceedings.

[42]  Jie Zhang,et al.  Oral Mucosal Drug Delivery , 2002, Clinical pharmacokinetics.

[43]  T. Schettler,et al.  Health risks posed by use of Di-2-ethylhexyl phthalate (DEHP) in PVC medical devices: a critical review. , 2001, American journal of industrial medicine.

[44]  E. Billaud.  Clinical pharmacology of immunosuppressive drugs: year 2000--time for alternatives. , 2000, Therapie.

[45]  J. Hooff,et al.  Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. , 1998, Transplantation proceedings.

[46]  P. C. Smith,et al.  Abdominal complications after lung transplantation. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.